A5027606708- Cancer Immunotherapy and Biomarkers
- Immune cells in cancer
- Immunotherapy and Immune Responses
- Drug-Induced Hepatotoxicity and Protection
- Bladder and Urothelial Cancer Treatments
- Immune Cell Function and Interaction
- Acute Myeloid Leukemia Research
- Pregnancy and preeclampsia studies
- Colorectal Cancer Treatments and Studies
- Liver Disease Diagnosis and Treatment
- Radiation Therapy and Dosimetry
- Pregnancy and Medication Impact
- Phagocytosis and Immune Regulation
- Immune responses and vaccinations
- Epigenetics and DNA Methylation
- Organ Transplantation Techniques and Outcomes
- Atrial Fibrillation Management and Outcomes
- Pharmacology and Obesity Treatment
- Hormonal Regulation and Hypertension
- Spaceflight effects on biology
- Ferroptosis and cancer prognosis
- Hepatitis B Virus Studies
- Cytokine Signaling Pathways and Interactions
- Effects of Radiation Exposure
- Liver physiology and pathology
Icahn School of Medicine at Mount Sinai
2021-2025
Tisch Hospital
2023-2024
Tisch Cancer Institute
2023
Columbia University Irving Medical Center
2018-2021
Université Paris-Sud
1978
Hospital de Clínicas
1974
Age is a major risk factor for cancer, but how aging impacts tumor control remains unclear. In this study, we establish that of the immune system, regardless age stroma and tumor, drives lung cancer progression. Hematopoietic enhances emergency myelopoiesis, resulting in local accumulation myeloid progenitor–like cells tumors. These are source interleukin (IL)–1⍺, which enhanced response. The age-associated decline DNA methyltransferase 3A IL-1⍺ production, disrupting IL-1 receptor 1...
Abstract Introduction: Chronic inflammation can contribute to growth and immune evasion of solid tumors, with multiple cytokines chemokines implicated in this process. We previously showed that disrupting the Th2 response systemically by blocking IL-4 signaling activate dendritic cells T effector generate a robust against tumor antigens pre-clinical lung cancer models (Maier, B., et al., A conserved dendritic-cell regulatory program limits anti-tumour immunity. Nature,...
DNMT3A encodes an enzyme that carries out de novo DNA methylation, which is essential for the acquisition of cellular identity and specialized functions during differentiation. most frequently mutated gene in age-related clonal hematopoiesis. As such, mature immune cells harboring mutations can be readily detected elderly persons. Most associated with hematopoiesis are heterozygous predicted to cause loss function, indicating haploinsufficiency predominant pathogenic mechanism. Yet, impact...
There are limited data on the causative agents and characteristics of drug-induced liver injury in pregnant individuals. Data from patients with enrolled ongoing multicenter Drug-Induced Liver Injury Network between 2004 2022 occurring during pregnancy or 6 months postpartum were reviewed compared cases nonpregnant women childbearing age. Among 325 individuals age Network, 16 (5%) occurred postpartum. Compared women, pregnancy-related was more severe ( P <.05). One elective termination...
TPS2696 Background: For resectable stage II/III non-small cell lung cancer (NSCLC), neoadjuvant chemoimmunotherapy has become standard of care. Patients with Stage I disease (as per AJCC 8) were excluded from studies given prior data demonstrating no survival benefit perioperative chemotherapy. However, even patients 1A (< 2cm) tumors have a 30% chance recurrence (Altorki et al, NEJM 2023). Recent research revealed that tumor-infiltrating myeloid cells express an IL-4 responsive...
e16320 Background: Immunotherapy has markedly improved the survival of patients with advanced hepatocellular carcinoma (HCC). Early-stage HCC is potentially curable through surgical resection, though recurrence seen in up to 70% patients. Neoadjuvant immunotherapy may reduce risk local and distal recurrences currently being studied several early-phase clinical trials. Here we review our single-institution experience neoadjuvant 66 resectable HCC. Methods: We identified 17 from NCT04123379...
Sustained inflammation and hepatocyte injury in chronic liver disease activate HSCs to transdifferentiate into fibrogenic, contractile myofibroblasts. We investigated the role of protocadherin 7 (PCDH7), a cadherin family member not previously characterized liver, whose expression is restricted HSCs.
Summary Immunotherapy is a treatment for many types of cancer, primarily due to deep and durable clinical responses mediated by immune checkpoint blockade (ICB) 1, 2 . Prostate cancer notable exception in that it generally unresponsive ICB. The standard advanced prostate androgen-deprivation therapy (ADT), form castration (CTX). ADT initially effective, but over time patients eventually develop castration-resistant (CRPC). Here, we focused on defining tumor-cell intrinsic factors contribute...
<h3>Background</h3> Most cancers are diseases of aging. But the lack an unbiased inquiry into cellular basis for link between aging and tumorigenesis has left study cancer incomplete. Filling this gap in knowledge could help characterize early stages aid design prevention strategies. Non-small cell lung (NSCLC) is strongly associated with As it most common cause cancer-related mortality, we sought to decipher effect on host response NSCLC pathogenesis. <h3>Methods</h3> We combined...
Monocyte-derived macrophages (mo-macs) and polymorphonuclear leukocytes (PMNs) are abundant in non-small cell lung cancer (NSCLC) hepatocellular carcinoma (HCC), limiting response to immune checkpoint blockade (ICB) by promoting an immunosuppressive tumor microenvironment (TME). Preclinical work shows that tumor-derived CCR2 ligands IL8 play a key role recruiting mo-macs PMNs, respectively, the TME. Disrupting these signaling pathways augments ICB mouse models, but clinical benefit has yet...
<h3>Background</h3> Immune checkpoint blockade (ICB) has revolutionized cancer treatment; however, most patients fail to achieve the full clinical benefit of ICB. Although anti-PD-1 agents are FDA-approved for non-small cell lung (NSCLC) and hepatocellular carcinoma (HCC), only a minority respond clinically.<sup>1,2</sup> This limited response is likely due, in part, immunosuppressive factors within tumor microenvironment (TME). Myeloid cells, specifically monocyte-derived macrophages...
Abstract Type-2 cytokines are hypothesized to promote an immune-permissive milieu for cancer grow. Through scRNAseq and CITEseq on human non-small cell lung (NSCLC) the krasG12Dp53−/− model we previously described a tumor-enriched dendritic program of concomitant immunosuppression activation which termed “mregDC,” that was also notable strong Th2 immune signature. We subsequently blocked canonical cytokine IL-4 in vivo tumor-bearing mice, found this significantly decreased tumor burden,...
<h3>Background</h3> Although colorectal cancer (CRC) is traditionally considered to be immunologically inert, some subsets of cancer, particularly mismatch repair-deficient (MMRd) tumors, can highly responsive immune checkpoint blockade (ICB). Recent studies show -that even repair-proficient (MMRp) tumors respond combined PD-1/CTLA-4 ICB. Tumor-associated macrophages (TAMs) are an influential component the tumor microenvironment (TME), although exact role these cells in pathogenesis and...